Carregant...

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSO(TM)), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer (NSCLC), limits the long‐term benefits for patients. Thus, effective t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Oncol
Autors principals: Zang, Hongjing, Qian, Guoqing, Arbiser, Jack, Owonikoko, Taofeek K., Ramalingam, Suresh S., Fan, Songqing, Sun, Shi‐Yong
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7138398/
https://ncbi.nlm.nih.gov/pubmed/32003107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12645
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!